Other
CEPI
Total Trials
3
Recruiting
0
Active
3
Completed
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
Failure Rate
0.0%
0 terminated/withdrawn out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Phase 2
2(66.7%)
Phase 3
1(33.3%)
3Total
Phase 2(2)
Phase 3(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (3)
Showing 3 of 3 trials
NCT06844487Phase 3Active Not Recruiting
Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC
Role: collaborator
NCT05409261Phase 2Active Not Recruiting
Evaluation of the Immunogenicity and Safety of Ad26.COV2.S's COVID-19 Vaccine
Role: collaborator
NCT05409300Phase 2Active Not Recruiting
Evaluation of the Immunogenicity and Safety BBIBP-CorV Vaccine for COVID-19 in Adults in Guinea
Role: collaborator
All 3 trials loaded